50 results on '"Kim, Edward S."'
Search Results
2. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
3. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
4. MO29-3 A database of 1023 patients with NSCLC and uncommon EGFR mutations treated with afatinib: focus on Asian patients
5. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
6. Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
7. Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA
8. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer
9. Response to Letter to the Editor
10. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
11. Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis
12. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
13. Updates Regarding Biomarker Testing for Non–Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable
14. Gene Therapy in Head and Neck Cancer
15. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
16. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
17. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer
18. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
19. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial
20. Systematic Review of Brain Metastases in Patients With Non–Small-Cell Lung Cancer in the United States, European Union, and Japan
21. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment
22. Clinicopathologic Features of Advanced Squamous NSCLC
23. Improving the Care of Patients With Stage IB Non–Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers
24. Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry
25. Prognostic Implications of Tumoral Expression of Insulin Like Growth Factors 1 and 2 in Patients With Non–Small-Cell Lung Cancer
26. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
27. Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536
28. Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial
29. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
30. Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy
31. g-Protein Coupled Receptor Family C, Group 5, Member A ( gprc5a ) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients with Chronic Obstructive Pulmonary Disease and Non–Small-Cell Lung Cancer
32. Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
33. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells
34. Computed Tomography Findings Predicting Invasiveness of Thymoma
35. Air Travel after Biopsy-related Pneumothorax: Is It Safe to Fly?
36. Management of hyperuricemia in adults with or at risk of tumor lysis syndrome
37. The Multidisciplinary Approach to Thymoma: Combining Molecular and Clinical Approaches
38. Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy
39. Revisiting Stage IIIB and IV Non-small Cell Lung Cancer
40. Bidirectional Glenn with Existing Transvenous Cardioverter-Defibrillator Leads
41. Gefitinib plus docetaxel in non-small-cell lung cancer – Authors' reply
42. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
43. The Importance of Accurate Lymph Node Staging in Early and Locally Advanced Non-small Cell Lung Cancer: An Update on Available Techniques
44. Novel Combinations with Docetaxel in the Treatment of Non–Small-Cell Lung Cancer
45. Cetuximab as a Single Agent or in Combination with Chemotherapy in Lung Cancer
46. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report
47. Cetuximab in cancers of the lung and head & neck
48. Chemoprevention of lung cancer
49. Nonsmall-cell lung cancer: chemoprevention studies
50. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.